Evidence map›Paper›PMID 32598445›Full record

Trial reportThe journals of gerontology. Series A, Biological sciences and medical sciences2021

Effects of Fortetropin on the Rate of Muscle Protein Synthesis in Older Men and Women: A Randomized, Double-Blinded, Placebo-Controlled Study.

William Evans, Mahalakshmi Shankaran, Edna Nyangau, Tyler Field, Hussein Mohammed, Robert Wolfe, Scott Schutzler, Marc Hellerstein

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The journals of gerontology. Series A, Biological sciences and medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Evaluation of Fortetropin in geriatric and senior dogs with reduced mobility.The Canadian veterinary journal = La revue veterinaire canadienne · 2022
    Article
  6. Review
  7. Editorial: Sarcopenia: 2020.The journal of nutrition, health & aging · 2021
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

William EvansDepartment of Nutritional Sciences and Toxicology, University of California Berkeley.
Mahalakshmi ShankaranDepartment of Nutritional Sciences and Toxicology, University of California Berkeley.
Edna NyangauDepartment of Nutritional Sciences and Toxicology, University of California Berkeley.
Tyler FieldDepartment of Nutritional Sciences and Toxicology, University of California Berkeley.
Hussein MohammedDepartment of Nutritional Sciences and Toxicology, University of California Berkeley.
Robert WolfeDepartement of Geriatrics, University of Arkansas for Medical Sciences, Little Rock.
Scott SchutzlerDepartement of Geriatrics, University of Arkansas for Medical Sciences, Little Rock.
Marc HellersteinDepartment of Nutritional Sciences and Toxicology, University of California Berkeley.
University of California, Berkeley · USUniversity of Arkansas for Medical Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFortetropin is a proteo-lipid complex made from fertilized egg yolk and, in young men, has been shown to increase lean body mass.

methodsThe purpose of this study was to examine the effects of 21 days of Fortetropin supplementation on the fractional synthetic rate (FSR) of muscle protein in 10 healthy, older men and 10 women (66.4 ± 4.5 y). We used 2H2O labeling to measure FSR of multiple muscle protein ontologies. D3-creatine dilution was used to determine muscle mass at baseline. Subjects ingested 70% 2H2O for 21 day and saliva samples were collected to determine body 2H2O enrichment. A microbiopsy was obtained from the m. vastus lateralis on Day 21. Subjects were randomly assigned to Fortetropin (19.8 g/d) or placebo (cheese powder, 19.8 g/d).

resultsRestricting kinetic data to proteins with ≥2 peptides measured in at least 4 subjects per group resulted in 117 proteins meeting these criteria. The mean FSR for a majority of proteins in several muscle gene ontologies was higher in the Fortetropin group compared to placebo (32/38 myofibril proteins, 33/44 sarcoplasmic proteins, and 12/17 mitochondrial proteins) and this proportion was significantly different between groups using a binomial test and were independent of sex or baseline muscle mass.

conclusionsThe overall magnitude of the difference in muscle protein FSR of Fortetropin from placebo was 18%, with multiple gene ontologies affected. While these results should be confirmed in larger cohorts, they suggest that Fortetropin supplementation is effective for promoting muscle protein synthesis in older people.

Indexed as

AgedDouble-Blind MethodFemaleHumansMaleMiddle AgedMuscle ProteinsProteolipidsTime FactorsfortetropinMuscle ProteinsProteolipidsAging muscleMuscle protein synthesisSarcopenia

Identifiers

PMID32598445
PMCPMC7756695
OpenAlexW3037772162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.